<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJMM</journal-id><journal-title-group><journal-title>Open Journal of Medical Microbiology</journal-title></journal-title-group><issn pub-type="epub">2165-3372</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojmm.2017.71001</article-id><article-id pub-id-type="publisher-id">OJMM-73925</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Antibiotic Resistance in &lt;i&gt;Campylobacter&lt;/i&gt; Isolated from Patients with Gastroenteritis in a Teaching Hospital in Ghana
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Akosua</surname><given-names>B. Karikari</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kwasi</surname><given-names>Obiri-Danso</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Enoch</surname><given-names>H. Frimpong</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Karen</surname><given-names>A. Krogfelt</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Clinical Microbiology, University for Development Studies, Tamale, Ghana</addr-line></aff><aff id="aff4"><addr-line>Department of Microbiology &amp;amp; Infection Control, Statens Serum Institute, Copenhagen, Denmark</addr-line></aff><aff id="aff3"><addr-line>Department of Clinical Microbiology, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana</addr-line></aff><aff id="aff2"><addr-line>Department of Theoretical and Applied Biology, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>asbuks@yahoo.co.uk(ABK)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>02</month><year>2017</year></pub-date><volume>07</volume><issue>01</issue><fpage>1</fpage><lpage>11</lpage><history><date date-type="received"><day>December</day>	<month>11,</month>	<year>2016</year></date><date date-type="rev-recd"><day>Accepted:</day>	<month>February</month>	<year>3,</year>	</date><date date-type="accepted"><day>February</day>	<month>6,</month>	<year>2017</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Campylobacter
   is
   
  a leading
   
  causal agent of bacterial enteritis worldwide, but its prevalence is not well documented in
   
  Ghanaian hospitals. This study isolated
   
  Campylobacter 
  species from patients with enteritis or urinary tract infections attending Komfo Anokye Teaching Hospital and assessed the antibiogram profile of isolated species.
   
  Two hundred and two (202) in-patients and outpatients samples of all age groups diagnosed with enteritis or UTI infections were analyzed from
   
  May 2013 to August 2013. Campylobacter species were detected using selective agar (mCCDA) and confirmed on API
   
  Campy
   
  system (bioM&#233;rieux, France), with disk diffusion method determined the resistance profile of the species.
   
  Of the 128 enteritis and 74 UTI patients samples analyzed
  ,
   26 and 9 isolates were respectively confirmed as Campylobacter spp. giving a prevalence of 17.3% (35/202). Species identified were C. jejuni (40%), C. jejuni sub sp. doylei (2.8%), C. coli (37%) and C. lari (20%). Resistance was 92.3
  % 
  -
   
  100% each to erythromycin and the
   
  β
  -lactams, 61.5
  % 
  -
   
  86.7% to trimethoprim sulfamethoxazole, 92.3
  % 
  -
   
  93.3% to tetracycline, 46.2
  % 
  -
   
  80% to chloramphenicol, 0
  % 
  -
   
  60% to aminoglycosides and 0% to imipenem. Multidrug resistance of 97.1% was detected among species. Empirical
   
  treatment of Campylobacter enteritis with erythromycin and other common and cheap drugs may result in treatment failure in the face of high level resistance observed among the Campylobacter species.
 
</p></abstract><kwd-group><kwd>&lt;i&gt;Campylobacter&lt;/i&gt;</kwd><kwd> Antibiotic Resistance</kwd><kwd> Gastroenteritis</kwd><kwd> KATH</kwd><kwd> Ghana</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Campylobacter is a major agent of gastroenteritis worldwide, and in developing countries infection has strikingly increased in recent years [<xref ref-type="bibr" rid="scirp.73925-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref2">2</xref>] . Worldwide, Campylobacter causes between 400 - 500 million cases of diarrhea each year [<xref ref-type="bibr" rid="scirp.73925-ref3">3</xref>] . Campylobacter jejuni (sub sp. jejuni and doylei) and C. coli have mostly been implicated in human infections as C. lari and C. upsaliensis are less prevalent [<xref ref-type="bibr" rid="scirp.73925-ref4">4</xref>] . Campylobacteriosis is usually mild and self-limiting, but uncommonly associated with infections such as endocarditis, septicaemia, cholecystitis and urinary tract infections [<xref ref-type="bibr" rid="scirp.73925-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref6">6</xref>] . These infections typically warrant treatment as well as infections of the immunosuppressed, pregnant women, children, elderly and those with recurrent symptoms; in such cases the macrolides and fluoroquinolones are the first line drugs prescribed [<xref ref-type="bibr" rid="scirp.73925-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref8">8</xref>] . However, global reports of increasing resistance of Campylobacter to the drugs of choice and other clinically important antibiotics from human and animal origin are well established [<xref ref-type="bibr" rid="scirp.73925-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref10">10</xref>] . The resistance situation in developing countries such as Ghana might become worse as a result of widespread and unrestricted use of antibiotics as well as inadequate research into antimicrobial resistance.</p><p>In Ghana, diarrhea has been identified as the second most common health problem treated in outpatient clinics [<xref ref-type="bibr" rid="scirp.73925-ref11">11</xref>] . Routine screening of aetiological agents of diarrhea currently does not include Campylobacter as evident in the many hospital records in Ghana. In the proper management of diarrhea, a key agent such as Campylobacter cannot be ignored. This study reported on the prevalence of Campylobacter infections among patients presenting with gastric infections and the resistance profile of isolated species.</p></sec><sec id="s2"><title>2. Materials and Method</title><p>Study population and site</p><p>This study was undertaken at the Microbiology Laboratory of the Komfo Anokye Teaching Hospital (KATH), Kumasi. The hospital is the second-largest in Ghana and the only tertiary health institution in the Ashanti Region. It is a 1, 200 bed capacity referral hospital for 8 Regions in Ghana. In-patients at the various wards and out patients of KATH who were diagnosed with gastroenteritis or urinary tract infections (UTI) were enrolled in the study from May 2013 to August 2013. Patients of all age groups were recruited.</p><p>Sample processing, isolation and identification</p><p>Stool and mid-stream urine specimens submitted to the Microbiology Laboratory for bacteriological analysis were processed to obtain our target organism. A loopful of fresh faeces and 0.001 mL of urine were plated directly onto modified charcoal-cefoperazone-deoxycholate agar (mCCDA Oxoid CM0689) supplemented with CCDA selective supplement (Oxoid, SRO155E) using sterile loop and 0.001 calibrated loop respectively. The plates were kept in a 2.5 L anaerobic jar and Campy-Gen gas generating kit (Oxoid CN0025A) introduced to keep the microaerophilic condition at 42˚C for 48 hours. Campylobacter species were identified by morphological characteristics and biochemically by Gram stain, catalase and oxidase test. Colonies that were small curved Gram negative, oxidase and catalase positive were further analysed on API Campy to identify to species level (bioM&#233;rieux, France).</p><p>Antimicrobial Susceptibility test</p><p>Antimicrobial susceptibility test was performed by the disk diffusion method on Mueller-Hinton agar (Liofilchem-Italy) supplemented with 5% sheep blood; inoculated with 0.5 McFarland suspension and incubated under microaerophilic condition using Campy-Gen CO<sub>2</sub> generating kit at 42˚C for 24 hours [<xref ref-type="bibr" rid="scirp.73925-ref12">12</xref>] . Essayed antibiotics sourced from Rosco (Neo-Sensitabs<sup>TM</sup>, Denmark) included: Ampicillin (10 &#181;g/disc), chloramphenicol (30 &#181;g/disc), ciprofloxacin (5 &#181;g/disc), kanamycin (30 &#181;g/disc), erythromycin (15 &#181;g/disc), gentamicin (10 &#181;g/disc), nalidixic acid (30 &#181;g/disc), tetracycline (30 &#181;g/disc), cephalexin (30 &#181;g/disc), trimethoprim sulfamethoxazole (25 &#181;g/disc), norfloxacin (10 &#181;g/disc), cefotaxime (30 &#181;g/disc) and imipenem (10 &#181;g/disc). The diameter of inhibition zone sizes were measured and interpreted according to EUCAST- and CLSI 2013 breakpoints. Established breakpoints for enterobacteriaceae were used to interpret the results of norfloxacin, trimethoprim sulfamethoxazole, cefotaxime and kanamycin as CLSI Campylobacter breakpoints for these antibiotics has not yet been established. Quality control was achieved using E. coli (ATCC25922) and S. aureus (ATCC25923) strains.</p><p>Data Analysis</p><p>Descriptive analysis was carried out using percentages. Associations were determined using the Chi-square test at a significance level of &lt;0.05. All statistical tests were two-tailed. Stata 14.0 software was used for statistical analysis.</p><p>Ethical Approval</p><p>Ethical clearance was obtained from the joint Committee on Human Research Publications and Ethics of the School of Medical Sciences and the Komfo Anokye Teaching Hospital (CHRPE/RC/066/14). Specimens collected and processed were given codes; all identities on samples were removed, which made the patients anonymous.</p></sec><sec id="s3"><title>3. Results</title><p>Isolation rate of Campylobacter from patients with UTI and enteritis</p><p>Of the 128 enteritis and 74 UTI cases, 26 (20.3%) and 9 (12.2%) isolates were respectively confirmed as Campylobacter spp. giving a prevalence of 17.3% (<xref ref-type="table" rid="table1">Table 1</xref>). No significant difference was observed in the isolation rate of Campylobacter from enteritis and UTI infections (p = 0.1403). All the Campylobacter</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Isolation rate of Campylobacter from patients with UTI and enteritis</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Infection</th><th align="center" valign="middle" >No. samples</th><th align="center" valign="middle" >No. isolates identified</th><th align="center" valign="middle" >p-value</th></tr></thead><tr><td align="center" valign="middle" >Enteritis</td><td align="center" valign="middle" >128</td><td align="center" valign="middle" >26 (20.3)</td><td align="center" valign="middle"  rowspan="2"  >0.140</td></tr><tr><td align="center" valign="middle" >UTI</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >9 (12.2)</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >202</td><td align="center" valign="middle" >35 (17.3)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>species from enteritis were isolated from patients at the out-patient department (OPD), while 4 of the patients in the ward and 5 from the OPD UTI cases were positive for Campylobacter. About 88% (31/35) of cases came from the OPD and 11.4% (4/35) from the Wards.</p><p>Species specific prevalence of Campylobacter from patients with UTI and enteritis</p><p>Campylobacter coli (46.2%) were the dominant species recovered from enteritis followed by C. jejuni (38.5%) and C. lari (11.5%) but 44.4% C. jejuni, 44.4% C. lari and 11.1% C. coli were recovered from UTI infections. One (1) C. jejuni sub sp. doylei was obtained from enteritis but none was found in UTI infections (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>Demographic distribution of Campylobacter infections</p><p>Isolation rate of Campylobacter was highest in the 10 - 29 (34.3%) age group, followed by 30 - 49 (28.6%) and 0 - 9 (22.8.0%) with age group above 50 recording the least (14.3%). The proportion of female and male patients was 67.6% and 32.4% respectively.</p><p>Antibiotic resistance profiles of Campylobacter species from patients</p><p>Resistance among isolates from enteritis to the beta-lactams (Ampicillin, cefotaxime and cephalexin) was 96% - 100%; as 96% was to erythromycin, 92% to tetracycline, 81% to trimethoprim sulfamethoxazole and 54% to chloramphenicol. Against the quinolones resistance was 23% each to nalidixic acid and norfloxacin and 35% to ciprofloxacin. Resistance to the aminoglycosides was 42% to gentamicin and 8% to kanamycin. Resistance among UTI isolates to the beta-lactams, erythromycin and tetracycline was 100% each, 67% to trimethoprim sulfamethoxazole and 56% to chloramphenicol. Against the quinolones, resistance was 67% each to nalidixic acid, norfloxacin and ciprofloxacin as 44% and 11% was observed respectively against gentamicinand kanamycin. All isolates exhibited 0% resistance to imipenem (<xref ref-type="table" rid="table3">Table 3</xref>). The difference in resistance levels between enteritis and UTI isolates was highly significant (p &lt; 0.0001).</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Campylobacter spp. isolated from patients with UTI and enteritis</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Species</th><th align="center" valign="middle" >No. isolates</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle" >Enteritis n = 26</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >C. jejuni</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >38.5</td></tr><tr><td align="center" valign="middle" >C. jejuni sub. sp. doylei</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3.8</td></tr><tr><td align="center" valign="middle" >C. coli</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >46.2</td></tr><tr><td align="center" valign="middle" >C. lari</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >11.5</td></tr><tr><td align="center" valign="middle" >UTI n = 9</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >C. jejuni</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >44.4</td></tr><tr><td align="center" valign="middle" >C. jejuni sub. sp. doylei</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >C. coli</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >11.1</td></tr><tr><td align="center" valign="middle" >C. lari</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >44.4</td></tr></tbody></table></table-wrap><p>Resistance profile of C. jejuni and C. coli isolates from patients</p><p>Resistance among C. jejuni strains to the β-lactams and erythromycin was 100% each, to the quinolones, 33.3% - 46.7%, to the aminoglycosides 13.3% - 60%, 93.3% to tetracycline, 80% to chloramphenicol and 86.7% to trimethoprim sulfamethoxazole. Strains of C. coli showed resistance of 92.3% - 100% to the β- lactams and erythromycin, 0% - 23% to the quinolones and aminoglycosides, 92.3% to tetracycline, 46.2% to chloramphenicol and 61.5% to trimethoprim sulfamethoxazole. No resistance was observed among C. coli strains to nalidixic acid, norfloxacin and kanamycin. All strains of C. jejuni and C. coli were sensitive to imipenem. Generally resistance was common among C. jejuni strains than C. coli and the difference was significant, p &lt; 0.0001 (<xref ref-type="table" rid="table4">Table 4</xref>).</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Antibiotic resistance profile of Campylobacter spp. recovered from patients with UTI and enteritis</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="3"  >Percentage Resistance</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >Antibiotic</td><td align="center" valign="middle" >Species Identified N = 35</td><td align="center" valign="middle" >Enteritis N = 26</td><td align="center" valign="middle" >UTI N = 9</td><td align="center" valign="middle" >p-value &lt;0.0001</td></tr><tr><td align="center" valign="middle" >Nalidixic acid</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Norfloxacin</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Ciprofloxacin</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Ampicillin</td><td align="center" valign="middle" >97</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cefotaxime</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cephalexin</td><td align="center" valign="middle" >97</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Kanamycin</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Gentamicin</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Erythromycin</td><td align="center" valign="middle" >97</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Tetracycline</td><td align="center" valign="middle" >94</td><td align="center" valign="middle" >92</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Chloramphenicol</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >SXT</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>SXT = Trimethoprim sulfamethoxazole.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Resistance profile of C. jejuni and C. coli species</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Antibiotic</th><th align="center" valign="middle" >C. jejuni N = 15</th><th align="center" valign="middle" >C. coli N = 13</th><th align="center" valign="middle" >p-value &lt;0.0001</th></tr></thead><tr><td align="center" valign="middle" >Nalidixic acid</td><td align="center" valign="middle" >33.3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Norfloxacin</td><td align="center" valign="middle" >46.7</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Ciprofloxacin</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Ampicillin</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >92.3</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cefotaxime</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cephalexin</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >92.3</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Kanamycin</td><td align="center" valign="middle" >13.3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Gentamicin</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Erythromycin</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >92.3</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Tetracycline</td><td align="center" valign="middle" >93.3</td><td align="center" valign="middle" >92.3</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Chloramphenicol</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >46.2</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >SXT</td><td align="center" valign="middle" >86.7</td><td align="center" valign="middle" >61.5</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>SXT = Trimethoprim sulfamethoxazole.</p><p>Multidrug resistance in Campylobacter isolates from patients</p><p>Multidrug resistance (MDR) in this study was defined as resistance to three or more classes of antibiotics. Thirty four (34) out of the 35 Campylobacter species were multidrug resistant (97.1%). Isolates from enteritis showed MDR of 96.3% as 100% was observed among UTI isolates and the difference was significant; p = 0.0434 (<xref ref-type="table" rid="table5">Table 5</xref>).</p></sec><sec id="s4"><title>4. Discussion</title><p>The 17.3% prevalence obtained in our study is within the documented range of 20% in developing countries [<xref ref-type="bibr" rid="scirp.73925-ref13">13</xref>] and similar to other studies in Algeria (17.7%), Nigeria (16.5%) and Tanzania (18.0%) [<xref ref-type="bibr" rid="scirp.73925-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref16">16</xref>] . However, higher rates have been reported in Bangladesh (26%), Thailand (41%), Nigeria (62.7%) and Ethiopia (72.7%) [<xref ref-type="bibr" rid="scirp.73925-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref18">18</xref>] . Lower rates than in our study have also been reported in Zimbabwe (9.3%) and Egypt (5.8% - 9%) [<xref ref-type="bibr" rid="scirp.73925-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref19">19</xref>] . Abraham et al. also reported 6.6% and 12.8% in studies in urban and rural Ghana [<xref ref-type="bibr" rid="scirp.73925-ref20">20</xref>] . Although Campylobacter is normally recovered from children less than 2 years in most developing countries [<xref ref-type="bibr" rid="scirp.73925-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref22">22</xref>] , this study rather had higher prevalence in the 21 - 30 age group [<xref ref-type="bibr" rid="scirp.73925-ref2">2</xref>] . This may be attributed to the design of this study which did not focus on children with acute diarrhoea and also a reflection of the infection sources which were mostly obtained from the outpatient department which is usually dominated by these age groups in the study hospital. According to Friedman et al. two age peaks occur in Campylobacter acquisition in developed nations, which are ages less than1year and at 15 - 55 years [<xref ref-type="bibr" rid="scirp.73925-ref23">23</xref>] . Secondly, Campylobacter infections were more prevalent in female (68%) than in male (32%) patients. In studies by Fitzgerald et al. and Friedman et al., Campylobacter was more prevalent in male patients compared to females [<xref ref-type="bibr" rid="scirp.73925-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref24">24</xref>] . The results from this study probably speculate the gender distribution of Campylobacter infections in patients attending the Komfo Anokye Teaching hospital (KATH). Although no obvious reason has been reported on the impact of gender in Campylobacter acquisition, Gillespie et al. found that being an infant and a female has an increased risk of acquiring Campylobacter infection [<xref ref-type="bibr" rid="scirp.73925-ref25">25</xref>] .</p><p>Campylobacter jejuni (sub species jejuni) and C. coli are the most frequently encountered species in human infections [<xref ref-type="bibr" rid="scirp.73925-ref4">4</xref>] . This trend was observed in this study where 80% of our isolates were identified to be C. jejuni (43%) and C. coli (37%) species. Similar results have also been reported in Uganda, Ethiopia and Egypt [<xref ref-type="bibr" rid="scirp.73925-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref26">26</xref>] but Gwimi et al. recovered more C. coli (60.6%) than C. jejuni</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Multidrug resistance of Campylobacter species from patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="3"  >Multidrug Resistance</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >Infection</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >P-value</td><td align="center" valign="middle" >C. jejuni n = 15</td><td align="center" valign="middle" >C. coli n = 13</td><td align="center" valign="middle" >C. lari n = 7</td></tr><tr><td align="center" valign="middle" >Enteritis</td><td align="center" valign="middle" >26 (96.3)</td><td align="center" valign="middle" >0.043</td><td align="center" valign="middle" >11 (42.3)</td><td align="center" valign="middle" >12 (46.2)</td><td align="center" valign="middle" >3 (11.5)</td></tr><tr><td align="center" valign="middle" >UTI</td><td align="center" valign="middle" >9 (100)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4 (44.4)</td><td align="center" valign="middle" >1 (11.1)</td><td align="center" valign="middle" >4 (44.4)</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >35 (97.1)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>Multidrug resistance defined as resistance to 3 or more classes of drugs.</p><p>(24.5%) from human samples in Nigeria [<xref ref-type="bibr" rid="scirp.73925-ref2">2</xref>] . Campylobacter lari is known to infrequently cause human diseases compared to C. jejuni and C. coli. In this study, C. lari was largely found in UTI infections (44%) as well as patients with enteritis (11.5%). The isolates were from adult patients with age ranging from 62 - 77 years and a 3 year old child. Megraud et al. isolated urease positive C. lari from adult patients with diarrhoea and a child with appendicitis [<xref ref-type="bibr" rid="scirp.73925-ref27">27</xref>] .</p><p>Resistance of species to erythromycin was alarmingly high (92.3% - 100%), but macrolide resistance among Campylobacter has reportedly been low and stable for a long period of time [<xref ref-type="bibr" rid="scirp.73925-ref7">7</xref>] ; nonetheless 31%, 51%, and 79% have been reported from Bulgaria, Singapore, and Nigeria, respectively [<xref ref-type="bibr" rid="scirp.73925-ref28">28</xref>] . Erythromycin resistance in Campylobacter has been described as gradual processes that demands prolonged exposure [<xref ref-type="bibr" rid="scirp.73925-ref8">8</xref>] , and in agreement with this observation, Newman and colleagues have indicated that drugs such as erythromycin has been on the Ghanaian market for a relatively long period of time [<xref ref-type="bibr" rid="scirp.73925-ref29">29</xref>] . It is therefore reasonable to associate the high level resistance in our study to misuse and abuse of this drug due to the long exposure.</p><p>Similarly, high level resistance was observed against the β-lactams (96% - 100%) which is comparable to data from Egypt (100%) [<xref ref-type="bibr" rid="scirp.73925-ref10">10</xref>] . Literature reports suggest that majority of C. jejuni and C. coli strains are intrinsically resistant to the β-lactam agents caused by the production of β-lactamases which are frequently observed [<xref ref-type="bibr" rid="scirp.73925-ref30">30</xref>] . It can therefore be speculated that perhaps our C. jejuni and C. coli strains were β-lactamase producing strains accounting for the high resistance.</p><p>Resistance among C. jejuni and C. coli to the quinolones was below 50% which is lower than 72% and 80% documented in Spain, Thailand and Hong Kong respectively; but comparable to rates described in Germany (41% - 46%), USA and Canada (19% - 47%) [<xref ref-type="bibr" rid="scirp.73925-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref31">31</xref>] .</p><p>Resistance to tetracycline was 92.3% - 100% but 72% has been described in Spain and a much lower rate documented in Ethiopia where tetracycline resistance of 22% has been reported in human isolates [<xref ref-type="bibr" rid="scirp.73925-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref32">32</xref>] . Worldwide, the tetracyclines are a heavily used class of antibiotics both in human and veterinary medicine [<xref ref-type="bibr" rid="scirp.73925-ref33">33</xref>] , and in Ghana they are largely applied in animal husbandry leading to its widespread resistance [<xref ref-type="bibr" rid="scirp.73925-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref34">34</xref>] , possibly accounting for the high resistance currently observed. All isolates were sensitive to imipenem underlining speculation that carbapenems are an exception to the general β-lactam resistance and considered to be effective also in the treatment of campylobacteriosis [<xref ref-type="bibr" rid="scirp.73925-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref8">8</xref>] ; but there is the need for caution in its use; as 17% of the isolates exhibited intermediate susceptibility. Also, the low resistance against imipenem could partly be explained by the high cost resulting in infrequent prescription and less abuse.</p><p>Multidrug resistance among our isolates was 97.1% which agrees with reports from China (90%) but higher than rates established in France (37%) and Korea (56%) [<xref ref-type="bibr" rid="scirp.73925-ref35">35</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref36">36</xref>] [<xref ref-type="bibr" rid="scirp.73925-ref37">37</xref>] . High resistance levels discovered in our study may be attributed to misuse and unwarranted prescription of antibiotics by physicians who contribute largely to the growth and spread of antibiotic resistance [<xref ref-type="bibr" rid="scirp.73925-ref38">38</xref>] . Furthermore, self-medication is a common feature of patients attending this hospital due to readily available antibiotics across the counter in pharmaceutical stores, market stalls, by the roadside and from hawkers. This practice generally leads to antibiotic under use (sub-optimal dosages) that invariably increases selective pressure and antimicrobial resistance. Macrolides and fluoroquinolones still remain the drugs of choice for Campylobacter infections in some countries, however empirical treatment of patients presenting with Campylobacter enteritis at KATH with these drugs may result in treatment failure.</p></sec><sec id="s5"><title>5. Conclusion</title><p>The presence of multidrug resistant Campylobacter strains present among patients at Komfo Anokye Teaching Hospital indicates that most of the cheap and common antibiotics may not be reliable in the empirical treatment of patients with enteritis caused by Campylobacter and other related enteric pathogens and therefore necessary for laboratory confirmation of antibiotics. Nevertheless, imipenem and kanamycin proved to be highly effective. A more extensive, multi-regional study would aid in establishing the extent of Campylobacter infections in Ghana.</p></sec><sec id="s6"><title>Acknowledgements</title><p>We thank Prof. Niels Frimodt-M&#248;ller and ADMER (www.admerproject.org) for providing funds for this study. Our appreciation also goes to Statens Serum Institute for providing control strains and the Head and staff of the Microbiology Department of Komfo Anokye Teaching Hospital.</p></sec><sec id="s7"><title>Conflict of Interest</title><p>The authors declare that there is no conflict of interest regarding the publication of this paper.</p></sec><sec id="s8"><title>Cite this paper</title><p>Karikari, A.B., Obiri-Danso, K., Frimpong, E.H. and Krog- felt, K.A. (2017) Antibiotic Resistance in Campylobacter Isolated from Patients with Gastroenteritis in a Teaching Hospital in Ghana. Open Journal of Medical Microbiology, 7, 1-11. https://doi.org/10.4236/ojmm.2017.71001</p></sec></body><back><ref-list><title>References</title><ref id="scirp.73925-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Belongia, E. and Schwartz, B. (1998) Strategies for Promoting Judicious Use of Antibiotics by Doctors and Patients. Britain Medical Journal, 317, 668-671. https://doi.org/10.1136/bmj.317.7159.668</mixed-citation></ref><ref id="scirp.73925-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Shin, E. and Lee, Y. (2010) Characterization of Erythromycin-Resistant Porcine Isolates of Campylobacter coli. Microbial Drug Resistance, 16, 231-239. https://doi.org/10.1089/mdr.2010.0039</mixed-citation></ref><ref id="scirp.73925-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., Naren, G.W., Wu, C.M., Wang, Y., Dai, L., Xia, L.N., et al. (2010) Prevalence and Antimicrobial Resistance of Campylobacter Isolates in Broilers from China. Veterinary Microbiology, 144, 133-139. https://doi.org/10.1016/j.vetmic.2009.12.035</mixed-citation></ref><ref id="scirp.73925-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Payot, S., Avrain, L., Magras, C., Praud, K., Cloeckaert, A. and Chaslus-Dancla, E. (2004) Relative Contribution of Target Gene Mutation and Efflux to Fluoroquinolone and Erythromycin Resistance, in French Poultry and Pig Isolates of Campylobacter coli. International Journal of Antimicrobial Agents, 23, 468-472. https://doi.org/10.1016/j.ijantimicag.2003.12.008</mixed-citation></ref><ref id="scirp.73925-ref5"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Turkson</surname><given-names> P.K. </given-names></name>,<etal>et al</etal>. (<year>2008</year>)<article-title>Use of Drugs and Antibiotics in Ghana</article-title><source> Ghana Journal of Agric Science</source><volume> 41</volume>,<fpage> 23</fpage>-<lpage>33</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.73925-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Iovine, N.M. (2013) Resistance Mechanisms in Campylobacter jejuni. Virulence, 4, 230-240. https://doi.org/10.4161/viru.23753</mixed-citation></ref><ref id="scirp.73925-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Prats, G., Mirelis, B., Llovet, T., Mu&amp;#241oz, C., Miro, A.E. and Navarro, F. (2000) Antibiotic Resistance Trends in Enteropathogenic Bacteria Isolated in 1985-87 and 1995-98 in Barcelona. Antimicrobial Agents and Chemotherapy, 44, 1140-1145. https://doi.org/10.1128/AAC.44.5.1140-1145.2000</mixed-citation></ref><ref id="scirp.73925-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Luber, P., Wagner, J., Hahn, H. and Bartelt, E. (2003) Antimicrobial Resistance in Campylobacter jejuni and Campylobacter coli Strains Isolated in 1991 and 2001-2002 from Poultry and Humans in Berlin, Germany. Antimicrobial Agents and Chemotherapy, 47, 3825-3830. https://doi.org/10.1128/AAC.47.12.3825-3830.2003</mixed-citation></ref><ref id="scirp.73925-ref9"><label>9</label><mixed-citation publication-type="book" xlink:type="simple">Fitzgerald, F., Whichard, J. and Nachamkin, I. (2008) Diagnosis and Antimicrobial Susceptibility of Campylobacter Species. In: Nachamkin, I., Szymanski, C.M. and Blaser, M.J., Eds., Campylobacter, American Society for Microbiology, Washington DC, 227-243.</mixed-citation></ref><ref id="scirp.73925-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Newman, M.J., Frimpong, E., Donkor, E.S., Opintan, J.A. and Asamoah-Adu, A. (2011) Resistance to Antimicrobial Drugs in Ghana. Infection and Drug Resistance, 4, 215-220.</mixed-citation></ref><ref id="scirp.73925-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Gibreel, A. and Taylor, D.E. (2006) Macrolide Resistance in Campylobacter jejuni and Campylobacter coli. Journal of Antimicrobial Chemotherapy, 58, 243-255. https://doi.org/10.1093/jac/dkl210</mixed-citation></ref><ref id="scirp.73925-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Megraud, F., Chevrier, D., Desplaces, N., Sedallian, A. and Guesdon, J.L. (1988) Urease-Positive Thermophilic Campylobacter (Campylobacter laridis variant) Isolated from an Appendix and from Human Feces. Journal of Clinical Microbiology, 26, 1050-1051.</mixed-citation></ref><ref id="scirp.73925-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mshana, S.E., Joloba, M.L., Kakooza, A. and Kaddu-Mulindwa, D. (2009) Campylobacter spp. among Children with Acute Diarrhea Attending Mulago Hospital in Kampala-Uganda. African Health Sciences, 9, 201-205.</mixed-citation></ref><ref id="scirp.73925-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Gillespie, I.A., O’Brien, S.J., Frost, J.A., Tam, C., Tompkins, D., Neal, K.R., et al. (2006) The Campylobacter Sentinel Surveillance Scheme Collaborators. Investigating Vomiting and/or Bloody Diarrhea in Campylobacter jejuni Infection. Journal of Medical Microbiology, 55, Article ID: 741746. https://doi.org/10.1099/jmm.0.46422-0</mixed-citation></ref><ref id="scirp.73925-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Fitzgerald, C., Patrick, M., Jerris, R., Watson, R., Tobin-D’Angelo, M., Gonzalez, A., Polage, C., Wymore, K., Gillim-Ross, L., Sadlowski, J., Monahan, J., Hurd, S., Dahlberg, S., De Martino, M., Pentella, M., Razeq, J., Leonard, C., Jung, C., Juni, B., Robinson, T., Gittelman, R., Garrigan, C. and Nachamkin, I., Campylobacter Diagnostics Working Group (2011) Multicenter Study to Evaluate Diagnostic Methods for Detection and Isolation of Campylobacter from Stool. Annual Meeting of the American Society for Microbiology, New Orleans, 20 September 2011.</mixed-citation></ref><ref id="scirp.73925-ref16"><label>16</label><mixed-citation publication-type="book" xlink:type="simple">Friedman, C.R., Niemann, J., Wegener, H.C. and Tauxe, R.V. (2000) Epidemiology of Campylobacter jejuni Infections in the United States and Other Industrialised Nations. In: Nachampkin, I. and Blaser, M.J., Eds., Campylobacte, ASM Press, Washington DC, 121-138.</mixed-citation></ref><ref id="scirp.73925-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Lengerh, A., Moges, F., Unakal, C. and Anagaw, B. (2013) Prevalence, Associated Risk Factors and Antimicrobial Susceptibility Pattern of Campylobacter Species among under Five Diarrhoeagenic Children at Gondar University Hospital, Northwest Ethiopia. BMC Pediatrics, 13, 82. https://doi.org/10.1186/1471-2431-13-82</mixed-citation></ref><ref id="scirp.73925-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Samuel, S.O., Aboderin, A.O., Akanbi, A.A., Adegboro, B., Smith, S.I. and Coker, A.O. (2006) Campylobacter enteritis in Ilorin, Nigeria. East African Medical Journal, 83, 478-484.</mixed-citation></ref><ref id="scirp.73925-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Abraham, C.A., Agbodaze, D., Nakanot, A., Fari, A. and Longmatey, H.E.K. (1990) Prevalence and Antibiogram of Campylobacter jejuni in Domestic Animals in Rural Ghana. Archives of Environmental Health, 45, 59-62. https://doi.org/10.1080/00039896.1990.9935926</mixed-citation></ref><ref id="scirp.73925-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Simango, C. and Nyahanana, M. (1997) Campylobacter enteritis in Children in an Urban Community. Central African Medical Journal, 43, 172-175.</mixed-citation></ref><ref id="scirp.73925-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ashraful, H. and Rahman, K.M. (1991) Campylobacter jejuni as a Cause of Acute Diarrhea in Children: A Study of an Urban Hospital in Bangladesh. Journal of Tropical Medicine and Hygiene, 94, 50-54.</mixed-citation></ref><ref id="scirp.73925-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">David, N.T., Martin, J.B., Peter, E.P., Bodhidatta, L. and Wang, W.L.L. (1987) Erythromycin Resistant Campylobacter Infections in Thailand. Antimicrobial Agents Chemotherapy, 31, 438-442. https://doi.org/10.1128/AAC.31.3.438</mixed-citation></ref><ref id="scirp.73925-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Wren, B.W., Linton, D., Dorrell, N. and Karlyshev, A.V. (2001) Post Genome Analysis of Campylobacter jejuni. Journal of Applied Microbiology, 90, 36S-44S. https://doi.org/10.1046/j.1365-2672.2001.01352.x</mixed-citation></ref><ref id="scirp.73925-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Lindblom, G.B., Ahren, C., Changalucha, J., Gabone, R., Kaijser, B., Nilsson, L.A., et al. (1995) Campylobacter jejuni/coli and Enterotoxigenic Escherichia coli (ETEC) in Faeces from Children and Adults in Tanzania. Journal of Infectious Diseases, 27, 589-593.</mixed-citation></ref><ref id="scirp.73925-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Coker, A.O. and Adefeso, A.O. (1994) The Changing Patterns of Campylobacter jejuni C. coli in Lagos, Nigeria after Ten Years. East African Medical Journal, 74, Article ID: 437440.</mixed-citation></ref><ref id="scirp.73925-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Coker, A.O., Isokpehi, R.D., Thomas, B.N., Amisu, K.O. and Obi, C.L. (2002) Human Campylobacteriosis in Developing Countries. Emerging Infectious Disease, 8, 237-244. https://doi.org/10.3201/eid0803.010233</mixed-citation></ref><ref id="scirp.73925-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Clinical and Laboratory Standards Institute (2006) Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated Bacteria. Approved Guideline M45-A, CLSI, Wayne.</mixed-citation></ref><ref id="scirp.73925-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Ghana News Agency (2003) Hand Washing with Soap Could Prevent Death. Ghana News Agency, Accra.</mixed-citation></ref><ref id="scirp.73925-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Girgis, S.A., Rashad, S.S., Othman, H.B., Bassim, H.H., Kassem, N.N. and. El-Sayed, F.M. (2014) Multiplex PCR for Identification and Differentiation of Campylobacter Species and Their Antimicrobial Susceptibility Pattern in Egyptian Patients. International Journal of Current Microbiology and Applied Sciences, 3, 861-875.</mixed-citation></ref><ref id="scirp.73925-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Salihu, M.D., Junaidu, A.U., Magaji, A.A. and Yakubu, Y. (2012) Prevalence and Antimicrobial Resistance of Thermophilic Campylobacter Isolates from Commercial Broiler Flocks in Sokoto, Nigeria. Research Journal of Veterinary Sciences, 5, 51-58. https://doi.org/10.3923/rjvs.2012.51.58</mixed-citation></ref><ref id="scirp.73925-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Wieczorek, K. and Osek, J. (2013) Antimicrobial Resistance Mechanisms among Campylobacter. BioMed Research International, 2013, Article ID: 340605.https://doi.org/10.1155/2013/340605</mixed-citation></ref><ref id="scirp.73925-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Lehtopolku, M. (2011) Antimicrobial Resistance in Campylobacter jejuni and Campylobacter coli. Department of Internal Medicine and Medical Microbiology and Immunology, University of Turku, Turku, Finland and the Antimicrobial Resistance Unit, National Institute for Health and Welfare (Former National Public Health Institute, KT4, Yurku, Finland ISBN, 978-951-4718-8).</mixed-citation></ref><ref id="scirp.73925-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Belanger, A.E. and Shryock, T.R. (2007) Macrolide-Resistant Campylobacter: The Meat of the Matter. Journal of Antimicrobial Chemotherapy, 60, 715-723.https://doi.org/10.1093/jac/dkm300</mixed-citation></ref><ref id="scirp.73925-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Bezian, M.C., Ribou, G., Barberis-Giletti, C. and Megraud, F. (1990) Isolation of a Urease Positive Thermophilic Variant of Campylobacter lari from a Patient with Urinary Tract Infection. European Journal of Clinical Microbiology and Infectious Disease, 9, 895-897. https://doi.org/10.1007/BF01967506</mixed-citation></ref><ref id="scirp.73925-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Centre for Disease Control (2013) Incidence and Trends of Infection with Pathogens Transmitted Commonly through Food-Foodborne Disease Active Surveillance Network, 10 US Sites 1996-2012. Morbidity and Mortality Weekly Report, 62, 283-287.</mixed-citation></ref><ref id="scirp.73925-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Luangtongkum, T., Jeon, B., Han, J., Plummer, P., Logue, C.M. and Zhang, Q. (2009) Antibiotic Resistance in Campylobacter: Emergence, Transmission and Persistence. Future Microbiology, 4, 189-200. https://doi.org/10.2217/17460913.4.2.189</mixed-citation></ref><ref id="scirp.73925-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Gwimi, P.B., Faleke, O., Salihu, M.D., Magaji, A.A., Abubakar, M.B., Nwankwo, I.O., et al. (2015) Prevalence of Campylobacter Species in Faecal Samples of Pigs and Humans from Zuru Kebbi State, Nigeria. International Journal of One Health, 1, 1-5. https://doi.org/10.14202/IJOH.2015.1-5</mixed-citation></ref><ref id="scirp.73925-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Ewnetu, D. and Mihret, A. (2010) Prevalence and Antimicrobial Resistance of Campylobacter Isolates from Humans and Chickens in Bahir Dar, Ethiopia. Foodborne Pathogens and Disease, 7, 667-670. https://doi.org/10.1089/fpd.2009.0433</mixed-citation></ref></ref-list></back></article>